



Date: November 12, 2024

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd.,  
Exchange Plaza,  
Plot No. C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E)  
Mumbai – 400051

**NSE Symbol: UNIHEALTH**

Dear Sir/ Madam,

**Sub: Press Release on Half Yearly Financial Results for September 30, 2024.**

In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith is a copy of the Press Release made by the Company.

A copy of the press release is also being uploaded on the Company's website: [www.unihealthonline.com](http://www.unihealthonline.com).

You are requested to take the same on record.

Thanking you,

Yours faithfully,

For Unihealth Consultancy Limited

Binita Patel  
Company Secretary & Compliance Officer



**UniHealth Consultancy Limited**

(Formerly known as Unihealth Consultancy Private Limited)

Registered Office : H-13/14, Everest, 156, Tardeo Road, Mumbai - 400 034, Maharashtra, India.

+91 22 2354 4625 / 27    info@unihealthonline.com    www.unihealthonline.com | www.umchospitals.com

CIN No.: L85100MH2010PLC200491



## Unihealth Achieves ₹5 Crore Net Profit with 23% Growth

**Mumbai, November 11, 2024: UniHealth Consultancy Limited (NSE – UNIHEALTH)**, a global healthcare service provider with 200 commissioned beds across its tertiary care hospitals in Uganda and Nigeria, and a service portfolio that includes pharmaceutical distribution, medical value travel and healthcare consultancy services in India and across multiple geographies in Africa and Middle East, announced its Unaudited Financial Results for H1 FY25.

### Key Financial Highlights

Particulars (₹ Cr)	Consolidated		
	H1 FY25	H1 FY24	YoY
Total Income	25.26	22.85	10.55%
EBITDA	9.41	7.84	20.03%
EBITDA Margin (%)	37.25	34.31	294 Bps
Net Profit	5.23	4.24	23.19%
Net Profit Margin (%)	20.69	18.57	213 Bps

### Other Key Highlights:

In the first half of FY25, the segmental distribution of revenue for the company was as follows:

- Hospitals & Medical Centres contributed the largest share, generating Rs. 20.40 crore, which accounted for 80.76% of the total revenue.
- Consultancy Services brought in Rs. 1.62 crore, making up 6.41% of the revenue.
- Exports & Distribution generated Rs. 1.81 crore, contributing 7.17% to the overall revenue.
- Other Income added Rs. 1.43 crore, representing 5.66% of the total revenue.

Out of the total revenue, India contributed Rs. 3.95 crore, accounting for approximately 15.64%. Uganda contributed the largest share with Rs. 18.32 crore, representing about 72.53%. Nigeria contributed Rs. 2.11 crore (8.35%), followed by U.A.E with Rs. 0.42 crore (1.66%) and Tanzania with Rs. 0.46 crore (1.82%).

**Commenting on the performance, Dr. Akshay Parmar, Founder & Managing Director of UniHealth Consultancy said,** " Our H1 FY25 performance demonstrates the significant strides we've made in expanding our healthcare footprint and enhancing our service capabilities. The notable growth in income and profitability reflects our commitment to delivering high-quality healthcare solutions to our communities. The year-on-year gains in EBITDA and PAT margins underscore the strength of our operational efficiencies and our scalable approach.

The rebranding to UniHealth Hospitals Limited marks an important evolution in our focus toward hospital-based care, further establishing our position in the healthcare sector. A key milestone this half has been securing a majority stake in UMC Global Health Limited, increasing our shareholding to 51% and bringing it under our full operational umbrella as a subsidiary. This strategic move not only enhances our capabilities but also aligns with our broader growth strategy.

Looking forward, we're ambitious about our expansion plans, which include the development of over 1,000 tertiary care hospital beds across Africa and India and the establishment of more than 25 UniHealth Medical and Diagnostic Centres. We are also introducing specialized services—such as

Ophthalmology, IVF, and Cardiology—at our existing facilities in Uganda and Nigeria, significantly broadening our care offerings.

Our recent rebranding and acquisition efforts place us in a strong position to capitalize on the growing healthcare needs of the region, reinforcing Unihealth's vision of becoming a leading healthcare provider across the continent. We're enthusiastic about these developments and remain deeply committed to our mission of delivering exceptional healthcare services to those we serve."

### H1 FY25 Result Highlights of Unihealth Consultancy Limited

<b>Appointment of Independent Director</b>	Appointed Mr. Ajay Kumar Thakur as Independent Director, 30-year experience in the capital markets.
<b>Rebranding the Company</b>	Renaming the company 'UniHealth Consultancy Limited' to 'Unihealth Hospitals Limited'
<b>Secured Majority Stake in UMC Global Health Limited</b>	Increased capital contribution to UMC Global Health Limited, raising its shareholding from 50% to 51%, UMC Global Health Limited has become a subsidiary of the company.

### About Unihealth Consultancy Limited:

**UniHealth Consultancy Limited (NSE – UNIHEALTH)**, established in 2010 in Mumbai, is a prominent global healthcare service provider with a strong presence in Africa. The company operates in various healthcare sectors, encompassing medical centres, hospitals, consultancy services, pharmaceutical distribution, and medical travel.


Through its subsidiary, UniHealth Pharmaceuticals, it specializes in procuring and exporting pharmaceutical products, serving hospitals in Uganda, Nigeria, and Tanzania. Under the 'UMC Hospitals' brand, UniHealth manages two multi-speciality facilities with a combined 200-bed capacity in Uganda and Nigeria, along with a dialysis centre in Tanzania. Additionally, UniHealth is actively involved in healthcare consultancy projects in Kenya and Angola and serves as a reliable distributor for Indian pharmaceutical companies across various African nations.

The Company was successfully listed on the NSE Emerge in September 2023. In FY24, the company reported Revenue of ₹ 50 Cr, EBITDA of ₹ 19 Cr and PAT of ₹ 10 Cr.

### Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

### For Further Information Please Contact Corporate Communication Advisor

	<b>Kirin Advisors Private Limited</b> Sunil Mudgal – Director <a href="mailto:sunil@kirinadvisors.com">sunil@kirinadvisors.com</a> +91 98692 75849
---	---

